POMDOCTOR LIMITED Successfully Completes Initial Public Offering in the U.S. Market

POMDOCTOR LIMITED Completes Successful Initial Public Offering

On October 9, 2025, POMDOCTOR LIMITED (Nasdaq: POM), a prominent online medical services provider in China, announced the successful closing of its initial public offering (IPO). The company issued 5,000,004 American Depositary Shares (ADSs), each priced at $4.00, thereby raising around $20 million before deducting underwriting fees and other expenses.

This launch is a pivotal moment for POMDOCTOR, which focuses on providing online health solutions for chronic disease management. The company’s IPO commenced trading on the Nasdaq Global Market on October 8, under the ticker symbol “POM,” with significant anticipation from investors and stakeholders alike.

As part of the IPO process, Joseph Stone Capital, LLC served as the underwriter, overseeing the offering conducted on a firm commitment basis. Investors may also be aware that there is an additional option allowing underwriters to purchase another 750,000 ADSs within 45 days from the date of the final prospectus.

The registration statement for this offering was filed with the U.S. Securities and Exchange Commission (SEC) and received the go-ahead on September 30, 2025. Those interested in obtaining the final prospectus can reach out via email, standard mail, or a phone call to Joseph Stone Capital, LLC, with options for reviewing it on the SEC’s official website as well.

POMDOCTOR LIMITED has established itself as a crucial player in China's rapidly evolving telehealth space, gaining recognition for its extensive network of contracted doctors and commitment to chronic disease management. According to Frost & Sullivan, it ranked sixth in the nation's Internet hospital market in 2022, underscoring its role in bridging the gap between patients and healthcare providers.

The company’s business model integrates a broad spectrum of healthcare services, efficiently connecting patients, medical professionals, and pharmaceutical services, solidifying its vision to enhance healthcare delivery.

Moreover, POMDOCTOR aims to provide effective prevention and treatment solutions, reducing the suffering of patients dealing with chronic illnesses. Transparency and efficiency are at the forefront of its operational strategy, as it works to streamline the healthcare supply chain through technology and innovation.

In light of its IPO and future expansion, POMDOCTOR has positioned itself for growth in both the online medical services arena and the broader healthcare industry. Stakeholders and investors are keenly observing the company, considering its potential to become the most trusted healthcare platform in China.

As POMDOCTOR looks ahead, it navigates the challenges and opportunities of being a publicly traded entity. The company remains committed to delivering quality medical services while expanding its footprint in the industry. By adopting new technologies and maintaining high standards, POMDOCTOR is set to meet the increasingly complex needs of healthcare consumers in today's digital age.

In summary, POMDOCTOR LIMITED's IPO marks a significant advancement in its journey, highlighting its pioneering efforts within China's healthcare landscape. For more information about the company and its services, interested parties can visit their website. The path ahead promises growth as POMDOCTOR continues its mission to transform chronic disease management through accessible online healthcare solutions.